Mutalik Sharad, Shah Swapnil, Sidwadkar Varsha, Khoja Meenaz
*Department of Dermatology, Maharashtra Medical Foundation-Joshi Hospital, Pune, India; †Department of Dermatology, Shah Skin and Laser Center, Solapur, India.
Dermatol Surg. 2017 Nov;43(11):1339-1347. doi: 10.1097/DSS.0000000000001190.
Understanding the pathogenesis of vitiligo has lead to innovation of new drugs and new uses of the existing drugs to enhance treatment outcome.
The aim of this observational pilot study was to assess the role of cyclosporine (CsA) to tackle the commonest aesthetic problem "perilesional halo" after autologous noncultured melanocyte-keratinocyte cell transplant (NCMKT) for localized, stable vitiligo.
Of the total 50 enrolled patients who underwent NCMKT for stable/resistant vitiligo, aged 12 to 68 years (mean 29.92 years), 18 were male and 32 were female. Group I (n = 25) patients did not receive any postoperative treatment. Group II (n = 25) patients received CsA postoperatively at 3 mg·kg·d for 3 weeks followed by 1.5 mg·kg·d for 6 weeks.
In Group I, results were as follows: 28% (n = 7) achieved >75% repigmentation, 16% (n = 4) achieved 50% to 75% repigmentation, 52% (n = 13) achieved 25% to 50% repigmentation, and 4% (n = 1) achieved <25% repigmentation. In Group II, 100% (n = 25) achieved >75% (median 90.7%) repigmentation post-NCMKT at the end of 6 months.
This new drug regimen using CsA resulted in rapid and uniform repigmentation without leaving any perilesional halo in Group II patients after NCMKT.
对白癜风发病机制的了解促使了新药的研发以及现有药物新用途的探索，以提高治疗效果。
本观察性试点研究旨在评估环孢素（CsA）在自体非培养黑素细胞 - 角质形成细胞移植（NCMKT）治疗局限性稳定型白癜风后解决最常见美学问题“皮损周围晕环”方面的作用。
共有50例年龄在12至68岁（平均29.92岁）、因稳定型/难治性白癜风接受NCMKT的患者入组，其中男性18例，女性32例。第一组（n = 25）患者术后未接受任何治疗。第二组（n = 25）患者术后接受CsA治疗，剂量为3mg·kg·d，持续3周，随后为1.5mg·kg·d，持续6周；
在第一组中，结果如下：28%（n = 7）色素恢复>75%，16%（n = 4）色素恢复50%至75%，52%（n = 13）色素恢复25%至50%，4%（n = 1）色素恢复<25%。在第二组中，6个月结束时，100%（n = 25）患者在NCMKT后色素恢复>75%（中位数90.7%）。
在NCMKT后的第二组患者中，这种使用CsA的新药物方案导致色素快速均匀恢复，且未留下任何皮损周围晕环。
